» Articles » PMID: 25034069

The MOGE(S) Classification of Cardiomyopathy for Clinicians

Overview
Date 2014 Jul 19
PMID 25034069
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Most cardiomyopathies are familial diseases. Cascade family screening identifies asymptomatic patients and family members with early traits of disease. The inheritance is autosomal dominant in a majority of cases, and recessive, X-linked, or matrilinear in the remaining. For the last 50 years, cardiomyopathy classifications have been based on the morphofunctional phenotypes, allowing cardiologists to conveniently group them in broad descriptive categories. However, the phenotype may not always conform to the genetic characteristics, may not allow risk stratification, and may not provide pre-clinical diagnoses in the family members. Because genetic testing is now increasingly becoming a part of clinical work-up, and based on the genetic heterogeneity, numerous new names are being coined for the description of cardiomyopathies associated with mutations in different genes; a comprehensive nosology is needed that could inform the clinical phenotype and involvement of organs other than the heart, as well as the genotype and the mode of inheritance. The recently proposed MOGE(S) nosology system embodies all of these characteristics, and describes the morphofunctional phenotype (M), organ(s) involvement (O), genetic inheritance pattern (G), etiological annotation (E) including genetic defect or underlying disease/substrate, and the functional status (S) of the disease using both the American College of Cardiology/American Heart Association stage and New York Heart Association functional class. The proposed nomenclature is supported by a web-assisted application and assists in the description of cardiomyopathy in symptomatic or asymptomatic patients and family members in the context of genetic testing. It is expected that such a nomenclature would help group cardiomyopathies on their etiological basis, describe complex genetics, and create collaborative registries.

Citing Articles

Non-coding RNAs affecting NLRP3 inflammasome pathway in diabetic cardiomyopathy: a comprehensive review of potential therapeutic options.

Radmehr E, Yazdanpanah N, Rezaei N J Transl Med. 2025; 23(1):249.

PMID: 40022088 PMC: 11871836. DOI: 10.1186/s12967-025-06269-w.


Hypertrophic Cardiomyopathy with Special Focus on Mavacamten and Its Future in Cardiology.

Mlynarska E, Radzioch E, Dabek B, Leszto K, Witkowska A, Czarnik W Biomedicines. 2025; 12(12.

PMID: 39767581 PMC: 11727519. DOI: 10.3390/biomedicines12122675.


The new 2023 ESC guidelines for the management of cardiomyopathies: a guiding path for cardiologist decisions.

Grasso M, Bondavalli D, Vilardo V, Cavaliere C, Gatti I, Di Toro A Eur Heart J Suppl. 2024; 26(Suppl 1):i1-i5.

PMID: 38867869 PMC: 11167974. DOI: 10.1093/eurheartjsupp/suae002.


Screening and diagnosis of cardiovascular disease using artificial intelligence-enabled cardiac magnetic resonance imaging.

Wang Y, Yang K, Wen Y, Wang P, Hu Y, Lai Y Nat Med. 2024; 30(5):1471-1480.

PMID: 38740996 PMC: 11108784. DOI: 10.1038/s41591-024-02971-2.


Exploring TTN variants as genetic insights into cardiomyopathy pathogenesis and potential emerging clues to molecular mechanisms in cardiomyopathies.

Ghaffari Jolfayi A, Kohansal E, Ghasemi S, Naderi N, Hesami M, MozafaryBazargany M Sci Rep. 2024; 14(1):5313.

PMID: 38438525 PMC: 10912352. DOI: 10.1038/s41598-024-56154-7.